Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising new combo offers hope for patients with aggressive lymphoma

NCT ID NCT07372352

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Soochow University Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 16, 2026 · Updated 18 times

Summary

This study tests a new mix of three drugs—zeprumetostat, azacitidine, and mitoxantrone hydrochloride liposome—in adults whose peripheral T-cell lymphoma has come back or not responded to earlier treatments. About 26 people will receive up to 6 cycles of the combination, then up to 2 years of a single maintenance drug if they respond. The goal is to see how many patients' tumors shrink and how long the benefits last, while closely monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELLS LYMPHOMA (PTCL) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Soochow University

    RECRUITING

    Suzhou, Jiangsu, 215000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

PERIPHERAL T CELLS LYMPHOMA (PTCL)